The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020
Lightning bolt

Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227

July 25, 2019

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019

ESMO18 Preview 5 – A look at the evolving Renal Cell Carcinoma landscape

The changing face of renal cell cancer from several perspectives

October 16, 2018

What was old in cancer research is new again

A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients

September 13, 2018

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018

Adapting TCR therapies for different solid tumours

An in-depth look at Adaptimmune's TCR T cell therapy program

July 10, 2018

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018

A beautiful day

Update on TLR9 as a target and what we learn from the latest clinical data

June 12, 2018

Fitting it all together – what does the post ASCO Lung Cancer Landscape look like?

Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...

June 11, 2018

ASCO18 Review of targeted therapies and combination approaches

Highlights and Lowlights amongst targeted therapy data at ASCO 2018

June 7, 2018

ASCO18 Day 3 Highlights and Lowlights

Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.

June 5, 2018

Will KEYNOTE-042 change the standard of care in lung cancer?

Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).

June 3, 2018

ASCO18 Day 1 Highlights

The promise and pitfalls of Day 1 of #ASCO18

June 3, 2018

Why don’t all cancer patients with a high TIL respond to immunotherapy?

We explore the importance of looking under the hood at various expression levels...

May 30, 2018

Learning from IO-IO combo misses

Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?

May 29, 2018

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…

May 25, 2018

ASCO18 Preview on Biomarkers of Response

Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?

May 22, 2018

ASCO18 Preview 4 What’s Hot in Urothelial Carcinoma

A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18

May 21, 2018

ASCO18 Preview 3 – Take a Walk on Life

What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen

May 18, 2018

ASCO18 Preview 2 – a dozen key Posters to watch out for

Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?

May 16, 2018

ASCO18 Preview 1 – Magnificence or Atrocious?

What to watch out for at ASCO18 in the oral presentation sessions

May 15, 2018

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018